StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Siddharth Rai Mangala

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

bySiddharth Rai MangalaHorizon: NA (inferred Swing (≤2wk))28 Oct 2026via Zee Business (Live)

Entry—Next open
Target₹1,360
Total upside —
Stop loss₹1,319—
CMP₹1,335.43h ago
ActiveNA+1.84%upside left 2 wk left
Follow Siddharth Rai Mangala for new calls(28% target hit, 188 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 6 other Swing calls on DRREDDYSee 204 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 28 Oct, 8:12 pm IST
8 supporting2 neutral3 opposing
Supports the BUY call (8)

MACD above its signal line — bullish momentum

Technicals · macd·28 Oct · today

Past week's volume 1.6× the 30-day average

Technicals · volume·28 Oct · today

2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·27 Oct · yesterday

6 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·27 Oct · yesterday

Dr Reddy's Q2 Review: Brokerages Flag Margin Recovery As Key Growth Driver — Check Target Price, Potential Upside

NewsNdtv-Profit·26 Oct · 2d ago

(opens in new tab)
Neutral / worth noting (2)

Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·23 Oct · 5d ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (3)

RSI at 71 — overbought territory

Technicals · rsi·28 Oct · today

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 5d ago

(opens in new tab)

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 5d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Siddharth Rai Mangala

Every call and its outcome